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Abstract A search for inhibitors of the IL-6-mediated signal
transduction in HepG2 cells using secreted alkaline phosphatase
(SEAP) as reporter gene resulted in the isolation of galiella-
lactone (1) from fermentations of the ascomycete strain A111-95.
Galiellalactone inhibits the IL-6-induced SEAP expression with
IC50 values of 250^500 nM by blocking the binding of the
activated Stat3 dimers to their DNA binding sites without
inhibiting the tyrosine and serine phosphorylation of the Stat3
transcription factor. Due to its selective activity, galiellalactone
may serve as a lead compound for the development of new
therapeutic agents for diseases originating from the inappropri-
ate expression of IL-6 and as molecular tool to dissect the JAK/
STAT pathways. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Cytokines are intercellular signaling polypetides produced
by activated cells. In£ammation-associated cytokines include
interleukin-6 (IL-6), interleukin-1L, tumor necrosis factor
(TNF-K), interferon-Q (IFN-Q), and transforming growth fac-
tor L [1]. IL-6 is the main inducer of the acute-phase response
in liver cells and stimulates the production of most acute
phase proteins (APPs) [2^5]. IL-6 initiates its action by bind-
ing to its receptor, which is composed of the 80 kDa ligand-
binding subunit (IL6-R) and the signal-transducing subunit,
gp130 [6]. After ligand binding the gp130 subunits aggregate
into a complex consisting of the IL-6R, two gp130 molecules
and one IL-6 molecule [7]. This aggregation activates the
gp130-associated protein-tyrosine kinases Jak1, Jak2, and
Tyk2, which tyrosine phosphorylate gp130, themselves, and
signal transducer and activator of transcription (Stat) 3 and
1. Tyrosine phosphorylation of Stat3/1 occurs at a single res-
idue (tyrosine 705, Stat3; tyrosine 701, Stat1) which is located
in the conserved Src homology (SH2) domain allowing homo-
dimerization as well as heterodimerization [8]. During trans-
location to the nucleus Stat3 and Stat1 are speci¢cally phos-
phorylated on a serine by a yet unknown kinase which is
required for full transcriptional activation [9]. In the nucleus
the Stat dimers bind to speci¢c consensus sequences (IL-
6REII, class II IL-6 responsive elements) and activate the
transcription of the target genes including the genes of the
APPs [10,11].
In view of the central role of the IL-6-dependent JAK/
STAT pathway for the induction of the acute phase response,
we developed a cell-based screening system for the search of
new inhibitors of the IL-6-dependent signal transduction in
HepG2 cells. Screening of 3100 mycelial cultures of basidio-
mycetes, ascomycetes and deuteromycetes for the production
of inhibitors resulted in the isolation of galiellalactone (1), a
tetrahydro-isobenzofuranone derivative, from the ascomycete
strain A111-95. Galiellalactone has been described previously
as a weak inhibitor of gibberellic acid-induced de novo syn-
thesis of K-amylase in embryoless halves of wheat seeds [12].
In this paper the biological properties and the mode of action
of galiellalactone (1) on the IL-6 induced activation of the
JAK/STAT pathway in liver cells are reported.
2. Materials and methods
2.1. Producing organism, fermentation and isolation of galiellalactone
The ascomycete strain A111-95 was isolated from wood. The spe-
cies however could not be identi¢ed. The strain was kindly provided
by H. Anke and is deposited in the culture collection of the LB
Biotechnologie, Universita«t Kaiserslautern. For maintenance on
agar slants the strain was kept on YMG medium composed of: yeast
extract 0.4%, malt extract 1%, glucose 1%, pH 5.5 and agar 1.5% for
solid media. Fermentations were carried out in a Braun Biostat A-20
fermenter containing 20 liters of YMG medium with aeration (3 l air/
min) and agitation (120 rpm) at 22‡C. The production of galiellalac-
tone (1) was followed by the inhibitory e¡ect of various concentra-
tions of a crude extract of the culture £uid in the IL-6-dependent
reporter gene assays as described below. After 700 h of fermentation,
the culture £uid was separated from the mycelium by ¢ltration and
extracted with EtOAc. The solvent was evaporated and the crude
product (2.3 g) was separated by chromatography on silica gel (Merck
60) with cyclohexane:EtOAc (70:30) as eluent resulting in 1.2 g of an
enriched product. Preparative HPLC (Macherey-Nagel Nucleosil
100-7 C-18, column 40U250 mm) with water:MeOH (46:54) as eluent
yielded 635 mg galiellalactone (1). The structure elucidation was per-
formed by spectroscopic methods.
2.2. Biological assays
HepG2 cells (ATCC HB 8065) and HeLa S3 (ATCC CCL 2.2) were
maintained in DMEM medium supplemented with 10% fetal calf se-
rum (FCS) und 65 Wg/ml penicillin G and 100 Wg/ml streptomycin
sulfate. Jurkat cells (ATCC TIB 152) and HL-60 cells (ATCC
CCL240) were grown in RPMI 1640 medium with 10% FCS. The
assays for antimicrobial activity and cytotoxicity were carried out as
described previously [13]. Mutagenicity was tested as described by
Venitt et al. [14].
The in£uence of galiellalactone on the syntheses of macromolecules
in HepG2 cells was analyzed as follows. HepG2 cells were seeded
in 24 well plates (6U105 cells/ml in OPTIMEM containing 10%
FCS) and allowed to grow for 16 h. Galiellalactone and 0.1 WCi of
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[2-14C]thymidine, [2-14C]uridine or [1-14C]leucine, respectively, were
added and the cells were incubated for an additional 24 h. The me-
dium was removed and the cells were washed with ice-cold PBS. The
cells were lysed by addition of 1 ml TCA (15%) per well, the precip-
itate was collected by centrifugation at 21 000Ug for 10 min at 4‡C,
washed with 1 ml TCA (10%) and the radioactivity in the acid in-
soluble material was measured with a liquid scintillation counter.
2.3. Reporter gene assays
The reporter plasmid pMW-IRF7 was constructed by cloning eight
copies of a class II IL-6 responsive element (IL-6RE II) of the IRF
promoter (5P-GCTAGCGATTTCCCCGAAATGGCTAGC-3P with
overlapping NheI sites) [15] immediately upstream of a thymidine ki-
nase promoter-driven secreted alkaline phosphatase (SEAP) reporter
gene [16]. The 1.2 kb human TNF-K promoter was ampli¢ed by PCR
from genomic DNA extracted from HeLa S3 cells as described re-
cently [17]. The PCR product was cloned into the XhoI^HindIII site
of the pGL3-Basic vector (Promega) to generate the TNF-K pro-
moter-driven luciferase reporter plasmid pJR-TNF-pro. The plasmid
pCH110 for normalizing transfection e⁄ciency was obtained from
Amersham. The reporter plasmids pGE3-NF1 [16], pTK-activating
protein-1 (AP-1) [18], pGE3-GAS/ISRE and pGE3-NF-AT [19]
have been described recently. Transfection of HepG2 cells was per-
formed by electroporating (Bio-Rad, GenePulser) 1U107 cells/ml in
0.4 ml HEBS bu¡er (20 mM HEPES, pH 7.05, 137 mM NaCl, 5 mM
KCl, 0.7 mM Na2HPO4, 6 mM dextrose) together with 80 Wg of the
pMW-IRF7 plasmid at 500 V/cm. After electroporation the cells were
seeded at 2U105 cells/ml and allowed to recover for 16 h. For induc-
tion of SEAP expression, the cells were treated with 10 ng/ml IL-6
with or without test compounds in OPTIMEM containing 0.5% FCS.
The activity of the SEAP in the culture medium was determined 24 h
after transfection using the Phospha-Light chemoluminescent assay
(Tropix, MA, USA) with a luminometer according to the manufac-
turer’s instructions.
Jurkat cells were electroporated similarly (6U107 cells/ml in 0.2 ml
0.5U HEBS bu¡er, 50 Wg of the pJR-TNF-pro vector or pGE3-NF-
AT vector). After electroporation the cells were seeded in 96 well
plates (6U105 cells/ml in OPTIMEM containing 10% FCS) with
and without test compounds and reporter gene expression was in-
duced with 32 nM 12-O-tetradecanoylphorbol-13-acetate (TPA) and
2 WM ionomycin. The reporter gene activity was measured 24 h after
transfection as described above. Transfection of HeLa S3 cells with
pGE3-NF1, pGE3-GAS/ISRE or pTK-AP-1 and determination of the
activity of the expressed SEAP was performed as described previously
[20].
2.4. Western blot analysis
HepG2 cells were seeded at 5U105 cells/ml in 100 mm diameter
dishes and allowed to grow for 24 h. The cells were then washed
with OPTIMEM containing 0.5% FCS, fed with 10 ml of OPTIMEM
containing 0.5% FCS, incubated for an additional 48 h and pretreated
for 60 min with or without di¡erent concentrations of galiellalactone.
Thereafter the cells were treated with 50 ng/ml IL-6 for 20 min. Total
cell extracts were prepared by lysing the cells in 1.5 ml lysis bu¡er (1%
Triton X-100, 10 mM EDTA, 2 mM EGTA, 500 mM NaCl, 10 mM
NaF, 1 mM Na3VO4, 1:50 complete protease-inhibitor cocktail
(Roche Diagnostics), 50 mM Tris^HCl, pH 7.5). The cellular debris
was removed by centrifugation (3000Ug, 30 min, 4‡C) and unspeci¢c
binding was blocked by incubation with 90 Wl protein-A-Sepharose
(50:50 slurry in PBS, Amersham Pharmacia Biotech, UK) for 2 h at
4‡C. The suspensions were then centrifuged (3000Ug, 5 min, 4‡C) and
the supernatants were incubated with 5 Wl anti-Stat3 antibodies (New
England Biolabs, MA, USA) and rotated end-over-end overnight at
4‡C. 90 Wl protein-A-Sepharose (50:50 slurry in PBS, Amersham
Pharmacia Biotech, UK) was added to the samples and incubation
was continued for 2 h at 4‡C. Immunocomplexes were collected by
centrifugation, washed twice with bu¡er A (100 mM NaCl, 2 mM
EDTA, 0.2% NP-40, 10 mM Tris^HCl, pH 7.5), once with bu¡er B
(500 mM NaCl, 2 mM EDTA, 0.2% NP-40, 10 mM Tris^HCl, pH
7.5) and with bu¡er C (10 mM Tris^HCl, pH 7.5) and dissolved in
SDS-sample bu¡er. The samples were analyzed by SDS^polyacryl-
amide gel (6.5%) electrophoresis, transferred to nitrocellulose (Opti-
tran, Schleicher and Schu« ll, Germany) and probed with an anti-phos-
pho-Stat3 antibody (New England Biolabs, MA, USA) and then with
a goat anti-rabbit antibody conjugated to horseradish peroxidase. The
blots were detected by enhanced chemoluminescence (New England
Biolabs, MA, USA). Thereafter the blots were stripped and reprobed
with an anti-Stat3 antibody (New England Biolabs, MA, USA).
HepG2 cells were starved for 24 h in DMEM with 0.5% FCS,
pretreated with galiellalactone for 1 h and induced with 50 ng/ml
IL-6. Total cell extracts were prepared as described above and 50 Wg
of protein were loaded in each lane of the 10% SDS^polyacrylamide
gel. Following electrophoretic transfer to nitrocellulose, the membrane
was probed with an anti-phospho-p38-MAPK-antibody (New Eng-
land Biolabs, MA, USA) and then with a goat anti-rabbit antibody
conjugated to horseradish peroxidase. The blots were detected by
enhanced chemoluminescence (New England Biolabs, MA, USA).
Thereafter the blots were stripped and reprobed with an anti-p38-
MAPK-antibody (New England Biolabs, MA, USA).
2.5. Electrophoretic mobility shift assay (EMSA)
EMSAs were carried out essentially as described by Cantwell et al.
[21]. Nuclear extracts for Stat binding assays were prepared as fol-
lows. HepG2 cells were seeded at 5U105 cells/ml in 100 mm diameter
dishes and allowed to grow for 72 h. The cells were then starved for
24 h in OPTIMEM with 0.5% FCS, pretreated for additional 60 min
with di¡erent concentrations of galiellalactone and induced with
100 ng/ml IL-6 for 20 min. The medium was removed and the cells
were washed twice with ice-cold PBS and once with ice-cold PBS
containing 1 mM Na3VO4 and 5 mM NaF. Cells were then washed
with hypotonic bu¡er (20 mM HEPES pH 7.9, 20 mM NaF, 1 mM
Na3VO4, 1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
1:50 complete protease-inhibitor cocktail (Roche Diagnostics), and
150 Wl of hypotonic bu¡er containing 0.2% Nonidet P-40 was added.
Lysates were scraped into microcentrifuge tubes, and the nuclei were
pelleted by centrifugation at 16 000Ug for 20 s at 4‡C. The super-
natant was removed, and the pellet was resuspended in 30 Wl of high-
salt bu¡er (20 mM HEPES pH 7.9, 420 mM NaCl, 30% glycerol,
20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, 1:50 complete protease-inhibitor cocktail
and gently rocked at 4‡C for 30 min. Nuclear debris was removed by
centrifugation at 16 000Ug for 20 min at 4‡C. The extracts were
aliquoted and stored at 370‡C.
Binding reactions for EMSA experiments were as follows. 10 Wg of
nuclear protein was mixed with 4 Wl of 5Ubinding bu¡er (65 mM
HEPES pH 7.9, 0.75 mM EDTA, 40% glycerol, 0.1% Nonidet P-40),
1 Wg of poly(dI-dC) (Boehringer Mannheim), 1 mM DTT and approx-
imately 50 000 cpm (V0.3 ng) of 32P-labeled Stat binding probe in a
total volume of 20 Wl. The reaction mixtures were incubated at room
temperature for 20 min and 10 Wl were separated on a 4% polyacryl-
amide gel, transferred to 3MM paper (Whatman), dried under vac-
uum, and exposed to X-ray ¢lm. For competition binding assays,
unlabeled oligonucleotides were added to the reaction in 100U molar
excess and incubated at room temperature for 5 min prior to addition
of the probe. For supershift experiments, phospho-Stat3(Tyr-705) or
Stat3 antibodies (1^3 Wg) were added to the reaction mixtures, which
were then incubated at 4‡C for 1 h prior to addition of the labeled
probe.
The oligonucleotides used as EMSA probes were annealed and gel-
puri¢ed prior to labeling. The sequences of the upper strands of the
oligonucleotides used were as follows: IRF: 5P-CTAGCGATT-
TCCCCGAAATGGCTAG-3P [15] ; m67SIE: 5P-GATCCATTTCC-
CGTAAATC-3P [15,22]; m67SIEmut: 5P-GATCCGGGAGGGATT-
TACGGGGAAATGCTG-3P [23]. Double-stranded oligonucleotides
were labeled with polynucleotide kinase and [Q-32P]ATP.
3. Results
Galiellalactone (1) has been detected during fermentation
and isolation using SEAP reporter plasmids containing multi-
ple IL-6RE II in their promoter (pMW-IRF7). Transfection
of HepG2 cells and stimulation with 10 ng/ml IL-6 resulted in
a ¢ve-fold activation over the basal level of SEAP expression.
Galiellalactone (1) inhibited the IL-6 induced SEAP expres-
sion in a dose-dependent manner with IC50 values of
250^500 nM (50^100 ng/ml; Table 1). Higher concentrations
(s 2 Wg/ml) inhibited the IL-6-induced SEAP expression be-
low the basal level. Besides galiellalactone (1), smaller
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amounts of the biosynthetic precursors pregaliellalactone (2)
and deoxygaliellalactone (3) were isolated from fermentations
of the same fungus [24] (for structures see Fig. 1). Pregaliella-
lactone (2) inhibited the IL-6 induced SEAP expression
in transiently transfected HepG2 cells with IC50 values of
5^10 Wg/ml (Fig. 2), whereas deoxygaliellalactone (3) showed
only a weak inhibition of the IL-6-induced reporter gene ex-
pression at comparatively high concentrations (10^50 Wg/ml).
In order to test the speci¢city, we determined the e¡ect of
galiellalactone on the GAS/ISRE, AP-1, nuclear factor UB
(NF-UB), NF-AT and human TNF-K promoter-driven expres-
sion of the reporter genes SEAP or luciferase in HeLa S3 and
Jurkat cells.
The IFN-Q-induced expression of the GAS/ISRE-driven re-
porter plasmid (pGE3-GAS/ISRE) in transiently transfected
HeLa S3 cells was inhibited by galiellalactone far less e⁄cient
than the IL-6-dependent SEAP expression (IC50 : 10^15 WM,
Table 1). In addition galiellalactone inhibited the AP-1 and
NF-UB-mediated SEAP expression in transiently transfected
HeLa S3 cells with IC50 values of 10^15 WM (2^3 Wg/ml, Table
1). These e¡ects were comparable to the inhibition of the
IFN-Q-induced reporter gene expression. The same result
was obtained for the TPA and ionomycin induced NF-AT-
mediated SEAP expression in Jurkat T-cells (IC50 : 10^15
WM).
TNF-K is an important mediator of in£ammation. The reg-
ulation of TNF-K gene expression in human cells is complex
with di¡erences across species and cell types [25^27]. The tran-
scriptional activation of the human TNF-K promoter is de-
pendent on binding sites for NF-UB, NF-AT and AP-1 fam-
ilies of transcription factors [28,29]. We therefore investigated
the in£uence of galiellalactone on the expression of a human
TNF-K transcriptional reporter in Jurkat cells. Galiellalactone
inhibited the TPA/ionomycin-stimulated expression of the
hTNF-K promoter-mediated luciferase expression in Jurkat
cells with IC50 values of 1.3^2.5 WM (0.25^0.5 Wg/ml, Table 1).
Cellular DNA-, RNA-, and protein syntheses were exam-
ined in HepG2 cells by determining the incorporation of
[2-14C]thymidine, [2-14C]uridine and [1-14C]leucine in TCA-in-
soluble fractions. Up to a concentration of 25 WM (5 Wg/ml)
galiellalactone, only weak inhibitory e¡ects on all three mac-
romolecular syntheses could be observed during 24 h incuba-
tion suggesting that galiellalactone does not interfere with
replication, transcription and translation in a general manner
(data not shown).
Galiellalactone exhibited up to 128 Wg/ml only moderate
antibacterial, antifungal or cytotoxic activities. In the test
for mutagenicity no induction of revertants of S. typhimurium
TA 98 and TA 100 could be observed at 32 Wg/ml of any of
the isolated compounds (pour plate assay with and without
addition of rat liver microsomes) [14].
IL-6 induces the activation of Stat1 and Stat3 transcription
factors by phosphorylation of tyrosine 701 and serine 727 on
Stat1 and tyrosine 705 and serine 727 on Stat3 [8,9]. To elu-
cidate the mechanism responsible for the inhibition of the
IL-6-induced expression of the reporter gene, we examined
the e¡ect of galiellalactone on the phosphorylation of these
residues upon induction of HepG2 cells with IL-6 by Western
blot analysis using anti-Stat3 antibodies speci¢c for the phos-
phorylation on tyrosine 705 or serine 727 and an anti-Stat1
antibody speci¢c for the phosphorylation on tyrosine 701.
As shown in Fig. 3A^C treatment of HepG2 cells with
50 ng/ml IL-6 resulted in a strong induction of tyrosine phos-
phorylation of the Stat3 and Stat1 proteins as well as serine
phosphorylation of Stat3. Pretreatment of HepG2 cells with
galiellalactone and stimulation with 50 ng/ml IL-6 showed no
inhibition of the tyrosine and serine phosphorylation of both
transcription factors up to a concentration of 16 Wg/ml
(80 WM). These data suggest that galiellalactone does not
act as an inhibitor of one or several of the Janus-kinases
(Jak1, Jak2 and Tyk2) which phosphorylate the Stat3/Stat1
transcription factors [6,30].
An involvement of p38 mitogen-activated protein kinase
(MAPK) in the IL-6-induced phosphorylation on serine 727
Table 1
E¡ect of galiellalactone on SEAP or luciferase reporter gene expression in HepG2, HeLa S3 and Jurkat cells
Reporter gene assay; cell line Stimulus Galiellalactone IC50 (WM)
8UIL-6RE II-SEAP; HepG2 IL-6 (10 ng/ml) 0.25^0.5
5UGAS/ISRE-SEAP; HeLa S3 IFN-Q (10 ng/ml) 10^15
3UAP-1-SEAP; HeLa S3 TPA (50 ng/ml) 10^15
5UNF-UB-SEAP; HeLa S3 TNF-K (10 ng/ml) 10^15
5UNF-AT/AP-1-SEAP; Jurkat TPA (32 nM)+ionomycin (2 WM) 10^15
hTNF-K-pro-Luc; Jurkat TPA (32 nM)+ionomycin (2 WM) 1.3^2.5
The cells lines were transiently transfected with the indicated reporter gene constructs and the expression of the reporter genes was induced as
described in Section 2.
Fig. 1. Structure of galiellalactone (1) and its biosynthetic precursors deoxygaliellalactone (2) and pregaliellalactone (3).
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of Stat3 in hepatocytes was recently proposed [31]. In order to
determine whether galiellalactone a¡ects the activation of the
p38 MAPK, Western blot analysis was performed with an
antibody speci¢c for the phosphorylated form of p38 (threo-
nine 180/tyrosine 182). The results are shown in Fig. 4. In
contrast to the results obtained by Zauberman et al. [31] no
induction of p38 phosphorylation was observed in our experi-
ments after treatment of HepG2 cells with 50 ng/ml IL-6.
However, cotreatment of the cells with 16 Wg/ml galiellalac-
tone markedly induced the phosphorylation of p38 (Fig. 4).
These results are in correspondence to Schuringa et al. [32]
who showed that p38 MAPK is not directly involved in Stat3
serine 727 phosphorylation, and that blocking the p38 kinase
activity by the synthetic inhibitor SB203580 signi¢cantly in-
creased the IL-6-induced Stat3 transactivation by increasing
the level of Stat3 serine 727 phosphorylation. Therefore, p38
rather act as a negative regulator of IL-6-induced Stat3 trans-
activation by a yet unknown mechanism.
Since galiellalactone did not inhibit the phosphorylation of
the Stat 3 transcription factor we further characterized the
mechanism involved in the inhibition of IL-6 signaling by
analyzing the in£uence of galiellalactone on the binding of
activated (phosphorylated) Stat3 dimers to the high a⁄nity
m67SIE sequence [15,22]. EMSA’s were performed with nu-
clear extracts from HepG2 cells pretreated with various con-
centrations of galiellalactone and stimulated with 100 ng/ml
Fig. 2. E¡ect of galiellalactone (b), deoxygaliellalactone (P) and
pregaliellalactone (R) on IL-6-dependent SEAP reporter gene ex-
pression in HepG2 cells. HepG2 cells were transfected with a
8UIL-6 RE II-dependent SEAP reporter gene construct and stimu-
lated with 10 ng/ml IL-6 for 24 h with or without test compounds
as described in Section 2. Control (100%): stimulation only.
Fig. 3. E¡ect of galiellalactone on Stat3 and Stat1 phosphorylation.
HepG2 cells were pretreated for 1 h with or without galiellalactone
and stimulated with 50 ng/ml IL-6 for 30 min. Subsequently total
cell extracts were prepared and in case of (A) and (B) immunopreci-
pitated with an anti-Stat3 antibody prior to Western blot analysis
(experimental details are described in Section 2). A: Phosphoryla-
tion of Stat3 on tyrosine 705. B: Phosphorylation of Stat3 on serine
727. C: Phosphorylation of Stat1 on tyrosine 701.
Fig. 4. E¡ect of IL-6 and galiellalactone on p38 phosphorylation.
HepG2 cells were pretreated for 1 h with or without galiellalactone
and stimulated with 50 ng/ml IL-6 for 30 min. Subsequently total
cell extracts were prepared and analyzed by Western blotting.
Fig. 5. E¡ect of galiellalactone on DNA binding of activated Stat3
dimers. HepG2 cells were pretreated with or without galiellalactone
for 60 min and stimulated with 100 ng/ml IL-6 for 20 min. Subse-
quently nuclear extracts were prepared and tested for DNA binding
activity by EMSA with a m67SIE probe. Comp. (100U) : 100-fold
molar excess of unlabeled probe; o.P.: sample without nuclear ex-
tract; p-Stat3-Ab: 1 Wg of phospho-Stat3(Tyr-705) antibody was
added to the reaction mixture; Stat3-Ab: 1 Wg of Stat2 antibody
was added to the reaction mixture.
FEBS 24221 20-10-00
M. Weidler et al./FEBS Letters 484 (2000) 1^64
IL-6 for 20 min. As shown in Fig. 5 no detectable level of
Stat3 DNA binding was observed in nuclear extracts of un-
stimulated cells. Stimulation of HepG2 cells with IL-6 resulted
in a strong increase in STAT3 DNA binding. To show that
the retarded band in IL-6 treated cells was indeed Stat3, we
incubated the nuclear extracts either with Stat3 or phospho-
Stat3(Tyr-705) antibodies. Both antibodies completely abro-
gated the shifted band suggesting that the IL-6-activated
(Stat3)2bm67SIE complex contains Stat3 dimers. In addition
the IL-6-inducible DNA complex disappeared in the presence
of a 100-fold excess of the unlabeled probe (Fig. 5), and the
mutant m67SIE probe (m67SIEmut) failed to bind the Stat3
proteins (data not shown). These results indicate the compo-
sition and the speci¢city of the Stat3 binding to the DNA.
Nuclear extracts of galiellalactone treated cells showed
that even at the lowest tested galiellalactone concentration
(16 ng/ml) the binding of the activated Stat3 dimers was com-
pletely inhibited (Fig. 5). These results demonstrate that gal-
iellalactone inhibited the IL-6 signaling by preventing of the
DNA binding of the Stat3 proteins. Similar results were ob-
tained when the IRF EMSA probe was used (data not
shown).
4. Discussion
IL-6 is a multifunctional cytokine which is produced by a
large variety of cells and functions as a regulator of immune
response, acute-phase reactions and hematopoiesis [30]. De-
regulated expression of IL-6 contributes to a variety of patho-
physiological processes like autoimmune diseases, plasmacy-
toma-myeloma, in£ammation and coronary heart disease
[33,34]. In the hepatoma cell line HepG2 IL-6 can induce
the expression of a variety of APSs, such as ¢brinogen, K1-
antichymotrypsin, K1-acidglycoprotein and haptoglobulin by
activating the gp130/JAK/STAT pathway. In addition to these
proteins it induces serum amyloid A, C-reactive protein
(CRP) and K1-antitrypsin in human primary hepatocytes.
Small-molecule inhibitors that interfere with the IL-6 signal-
ing cascade leading to the expression of disease-related genes
would be expected to serve as novel therapeutic approaches
[35,36].
We identi¢ed galiellalactone as an inhibitor of the IL-6-de-
pendent JAK/STAT signaling cascade in a screening of fungal
extracts with a cell-based reporter assay. The compound in-
hibited the expression of an IL-6-responsive element-driven
reporter gene with IC50 values of 250^500 nM. The mecha-
nism by which galiellalactone blocks the IL-6-induced JAK/
STAT pathway seems to involve the direct inhibition of the
binding of Stat3 dimers to their regulatory elements as shown
by EMSA (Fig. 5). Furthermore we have demonstrated that
galiellalactone did not have any e¡ect on activation of the
Stat3 protein since the IL-6-induced tyrosine 701 and serine
727 phosphorylation was not a¡ected.
The distinct but related IFN-Q signaling pathway results in
tyrosine 701 phosphorylation of Stat1 and a homodimeric
complex of Stat1 binds to the IFN-Q activation sequence in
the promoter of responsive genes [37]. The expression of an
IFN-Q-induced GAS/ISRE-driven reporter gene was inhibited
by galiellalactone at 20^30 times higher concentrations (10^15
WM) than the IL-6-induced reporter gene expression. As in the
case for Stat3, the tyrosine 701 phosphorylation of the Stat1
protein was not a¡ected. At higher concentrations, galiellalac-
tone interfered with other analyzed signal transduction path-
ways. It only moderately blocked the induced expression of
NF-UB-, AP-1- and NF-AT-dependent reporter genes (IC50 :
10^15 WM), whereas the expression of a human TNF-K pro-
moter-driven reporter gene, which depends on the binding
sites for NF-UB, AP-1 and NF-AT transcription factors was
in£uenced at lower concentrations (IC50 : 1.3^2.5 WM).
Galiellalactone lost completely its biological activity after
24 h of incubation with a 10U molar excess of L-cysteine in
PBS. The crystal structures of tyrosine-phosphorylated Stat1
and Stat3 bound to DNA have been described recently
[38,39]. The Stat3 protein has a cysteine residue (Cys-468) in
its DNA-binding domain which is missing in Stat1. It seems
conceivable that the formation of a covalent bond between
the sulfur atom of Cys-468 in Stat3 and the carbon at position
3 of galiellalactone inhibits the binding of Stat3 to the DNA.
Moreover, the hydroxyl group of galiellalactone might be im-
portant for binding of galiellalactone to the DNA binding
pocket of Stat3 since the biosynthetic precursor deoxygaliella-
lactone showed a strongly reduced inhibitory activity on the
IL-6-dependent gene expression. The inhibition of the NF-UB-,
AP-1- and NF-AT-dependent reporter genes might be due to
reactions of galiellalactone with other cellular target proteins.
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